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Abstract
Introduction: Hepatitis-associated aplastic anemia is a common syndrome in patients with bone marrow failure.
However, hepatitis-associated aplastic anemia is an immune-mediated disease that does not appear to be caused
by any of the known hepatitis viruses including hepatitis C virus. In addition, to the best of our knowledge there
are no reported cases of patients with chronic hepatitis C virus infection developing aplastic anemia associated
with pegylated interferon alpha 2a treatment.
Case presentation: We report the case of a 46-year-old Greek man who developed severe aplastic anemia during
treatment with pegylated interferon alpha 2a for chronic hepatitis C virus infection. He presented with generalized
purpura and bruising, as well as pallor of the skin and mucous membranes. His blood tests showed pancytopenia.
He underwent allogeneic bone marrow transplantation after completing two courses of immunosuppressive
therapy with antithymocyte globulin and cyclosporin A.
Conclusions: The combination of a specific environmental precipitant represented by the hepatitis C virus
infection, an altered metabolic detoxification pathway due to treatment with pegylated interferon alpha 2a and a
facilitating genetic background such as polymorphism in metabolic detoxification pathways and specific human
leukocyte antigen genes possibly conspired synergistically in the development of aplastic anemia in this patient.
Our case clearly shows that the causative role of pegylated interferon alpha 2a in the development of aplastic
anemia must not be ignored.
Introduction
H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sam a j o rp u b l i c
health issue. In developed countries, HCV accounts for
20% of cases of acute hepatitis, 70% of cases of chronic
hepatitis, 40% of cases of end-stage cirrhosis, 60% of
cases of hepatocellular carcinoma, and 30% of liver
transplants [1]. Moreover, extrahepatic manifestations of
chronic HCV infection are clinically present in almost
40% of infected patients. These manifestations include
essential mixed cryoglobulinemia, sicca syndrome, mem-
branoproliferative glomerulonephritis, thrombocyto-
penia, and autoimmune hemolytic anemia (AIHA) [2].
Hepatitis-associated aplastic anemia (HAA) is a not
uncommon syndrome in patients with bone marrow
failure, with hepatitis documented in 2 to 5% of cases of
aplastic anemia (AA) occurring in the West [3,4] and 4
to 10% in the Far East [5]. Characteristically, the HAA
syndrome is more prevalent among young men. The
hepatitis generally follows a benign course, but the
onset of AA two to three months later is usually fatal if
left untreated. HAA may be induced by the presence of
HCV or hepatitis B virus infection, and also by infec-
tions with other viruses such as human immunodefi-
ciency virus (HIV), Epstein-Barr virus (EBV),
transfusion-transmitted virus and echovirus [6]. How-
ever, most cases of HAA are seronegative for the known
hepatitis viruses, including hepatitis A, B, C, and G (GB
virus C) [7]. The clinical features of the syndrome and
the patient’s response to immunosuppressive treatment
strongly indicate that the liver and marrow abnormal-
ities in patients with HAA are immune-mediated [8,9].
Pegylated interferon alpha 2a (PEG-IFN-a 2a) or 2b
plus ribavirin is currently the standard regimen for
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reactions, including flu-like symptoms, nausea, anorexia,
diarrhea, psychiatric symptoms, alopecia, injection-site
reactions, leukopenia, thrombocytopenia, hemolytic ane-
mia, cough, dyspnea, rash, pruritus, insomnia, and
ataxia, have been associated with PEG-IFN-a 2a plus
ribavirin treatment. Treatment with interferon (IFN)-a
has also been reported to trigger autoimmune phenom-
ena in up to 3% of cases, with AIHA being the most
prevalent and most significant phenomena seen in clini-
cal practice [10]. Furthermore, due to its inhibition of
cellular growth, interference with oncogene expression
and augmentation of lymphocyte cytotoxicity for target
cells, IFN-a may cause bone marrow suppression,
including potentially severe cytopenias and, very rarely,
AA [11].
The primary observed serious adverse side effect of riba-
virin treatment is hemolytic anemia. Ribavirin is an
antiviral nucleoside analogue; the mechanism of ribavirin-
induced hemolytic anemia has not been clearly estab-
lished. Anemia is most likely related to extensive ribavirin
accumulation in erythrocytes subsequent to active unidir-
ectional transmembraneous transport. Ribavirin exerts its
toxicity through an inhibition of intracellular energy meta-
bolism and oxidative membrane damage, leading to an
accelerated extravascular hemolysis by the reticulo-
endothelial system [12]. Lau et al. describe how ribavirin,
following uptake into cells, is phosphorylated and con-
verted to ribavirin triphosphates, which then must be
dephosphorylated for elimination from the cells [13].
However, because red blood cells lack dephosphorylation
enzymes, ribavirin accumulates in cells and destroys them,
causing hemolytic anemia. Severe anemia develops in
about 10% of patients treated with ribavirin, and they
require close monitoring of hemoglobin (Hb) levels and
often ribavirin dose reduction, which may compromise
sustained virologic response.
Herein, we report the development of AA in a patient
with chronic HCV infection following treatment with
PEG-IFN-a 2a plus ribavirin. By reviewing the literature
on the subject and the course of the patient’sd i s e a s e ,
we have come to the conclusion that, on balance, the
development of AA was a side effect of the patient’s
treatment with PEG-IFN-a 2a within a facilitating
genetic and environmental background.
Case presentation
A 46-year-old Greek man was diagnosed with HCV
infection (genotype 4 h) and a combination treatment of
PEG-IFN-a 2a (180 μg, weekly) and ribavirin (1200 mg/
day) was commenced for a period of 48 weeks. Before
starting the combination treatment his blood tests were
normal with a platelet count of 250,000 cells/mm
3,H b
of 16.3 g/dl, and a white blood cell (WBC) count of
6300 cells/mm
3. The treatment was well tolerated by
the patient with a normalization of his liver function
tests. Four months later he was referred to the depart-
ment of pathophysiology with a bleeding tendency and
unexplained fatigue of recent onset. No contact with a
benzene or pesticide was mentioned by the patient. A
physical examination revealed generalized purpura and
bruising, and pallor of the skin and mucous membranes.
The patient’s liver, spleen and lymph nodes were not
enlarged. Routine blood work showed severe pancyto-
penia with a platelet count of 20,000 cells/mm
3,H b
of 7.9 g/dl, reticulocytes at 0% and a WBC count of
600 cells/mm
3 with an absolute neutrophil count of
180 cells/mm
3. Further investigation showed the patient
had a normal liver function test and normal prothrom-
bin time. On admission, his serum HCV ribonucleic
acid (RNA) levels were more than 1 × 10
6 units/ml. Ser-
ology for HIV, and hepatitis A and B viruses was nega-
tive, as were immunoglobulin (Ig) M antibodies against
cytomegalovirus, parvovirus B19, herpes simplex viruses
1 and 2, and EBV. Further investigations showed the fol-
lowing: urea 20 mg/dl (normal range 17 to 50 mg/dl),
creatinine 1.0 mg/dl (normal range 0.7 to 1.4 mg/dl),
sodium 139 mMol/L (normal range 136 to 145 mMol/L),
potassium 3.8 mMol/L (normal range 3.5 to 5.0 mMol/
L), glucose 99 mg/dl (normal range 74 to 115 mg/dl),
calcium 8.8 mg/dl (normal range 8.6 to 10.2 mg/dl), amy-
lase 48 U/L (normal range 20 to 104 U/L), creatine phos-
phokinase 200 U/L (normal range 20 to 190 U/L), lactate
dehydrogenase 296 U/L (normal range 200 to 460 U/L),
uric acid 4.6 mg/dl (normal range 3.5 to 7.2 mg/dl), ery-
throcyte sedimentation rate 34 mm in the first hour (nor-
mal range 0 to 20 mm), and C-reactive protein 37.4 mg/L
(normal range 0 to 5 mg/L). Screening for several autoan-
tibodies was negative. Thyroid function tests and comple-
ment serum levels were normal. A serum protein
electrophoresis showed no hypogammaglobulinemia or
abnormal bands. A computed tomography examination
of the patient’s abdomen and thorax was unremark-
able. The patient’s bone marrow biopsy was profoundly
hypocellular with a decrease in all haematopoietic cells
(Figure 1); the bone marrow space was composed mostly
of fat cells and marrow stroma. The CD34 cell popula-
tion was more than 1%. Malignant infiltrates or fibrosis
were absent. Fluorescence-activated cell sorting analysis
of the patient’s bone marrow showed decreased marrow
elements with normal lymphocyte gate. A cytogenetic
examination showed the patient had a normal karyotype.
The presence of paroxysmal nocturnal hemoglobulinuria
was excluded by flow cytometry with the use of anti-
CD55 and anti-CD59 antibodies. Human leukocyte anti-
gen (HLA) typing revealed t h ep r e s e n c eo fD R B 1 * 0 7 0 1
and DRB1*1501 alleles. HLA matching identified a sister
with an identical HLA type.
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Page 2 of 5The diagnosis of severe AA was made in the patient.
Treatment with PEG-IFN-a 2a and ribavirin were discon-
tinued. However, after two weeks, the pancytopenia did
not resolve and the patient was started on immunosup-
pressive therapy with rabbit antithymocyte globulin
(Thymo-globulin, Genzyme; 15 mg/kg/day, for five conse-
cutive days) and cyclosporin A (6 mg/kg/day, in divided
doses every 12 hours). Prophylaxis against serum sickness
was instituted with methylprednisolone (2 mg/kg/day) for
five days with subsequent halving of the dose every week
until discontinuation on day 28. The patient had a partial
response that was noted on day 60 with a platelet count
of 27,000 cells/mm
3, Hb of 9.3 g/dl and WBC of 5000
cells/mm
3. The patient was dependent on red blood cell
and platelet transfusions and was on granulocyte colony
stimulating factor (400 μg/m
2/day, three times a week).
Therefore, on day 120 a second course of antithymocyte
globulin therapy was given. The patient received a full
cyclosporin A dose for six months, after which cyclos-
porin A was tapered off slowly (0.5 mg/kg/month).
During the period of aplasia, the patient was persistently
pyrexial and broadspectrum antibiotics in the form of
an antipseudomonal penicillin (piperacillin/tazobactam)
and a carbapenem (meropenem) were administered con-
secutively, as well as an antifungal agent (liposomal
amphotericin B).
Eight months after the first course of immunosuppres-
sive treatment, the patient’s Hb was 10.6 g/dl, platelet
count was 32,000 cells/mm
3 and WBC was 3590 cells/
mm
3 with an absolute neutrophil count of 2261 cells/
mm
3.A tt h a tt i m et h ep a t i e n tw a ss t i l lr e c e i v i n gb l o o d
and platelet transfusions. His serum HCV RNA levels
were more than 1 × 10
6 units/ml indicating that the
patient was continuously viremic. His liver function
tests remained normal during follow up. The patient
underwent allogeneic bone marrow transplantation. He
experienced a hemorrhagic stroke due to prolonged
thrombocytopenia and died during the recovery phase.
Discussion
AA is characterized by a diminished number of or
absent bone marrow precursor cells and peripheral cyto-
penias. The disease is estimated to occur in two to four
people per million per year [14,15]. Numerous studies
have shown that AA behaves as an immune-mediated
disease. Cytotoxic T cells expressing T-helper 1 cyto-
kines, especially IFN-g, have been implicated in the
pathophysiology of T cell-induced, Fas-mediated stem
cell apoptosis of CD34 target stem cells [16]. Why
T cells are activated in patients with AA is unclear.
A number of reports have documented a significantly
increased incidence of HLA-DR15 in patients with AA
[17]. Additionally, in a recent study, HLA-DRB1 gene
analysis showed an increased prevalence of DRB1*07 in
patients with AA compared with the normal population,
at 15.7% and 8.3%, respectively. This raises the possibi-
lity that HLA-DRB1*07 plays a significant role in the
development of AA [18]. Our patient had both
DRB1*0701 and DRB1*1501 alleles, which may indicate
that their presence is likely to allow for preferential pre-
sentation of peptides, such as viruses or drugs, to speci-
fic T cells, driving the autoimmune T cell-mediated
destruction of the patient’s hematopoietic cells. This
process might have been further enhanced both in
quantity and quality by the action of the IFN-a treat-
ment that the patient received.
However, the association of AA and chronic HCV
infection remains ill-defined. In a recent report, there
were two cases of patients with AA, unrelated to IFN-a
therapy, among 35 patients with chronic HCV infection
[19]. Another case of a patient with severe AA associated
with HCV infection has also been reported [20]. Several
other studies have shown that the prevalence of anti-
HCV antibodies in patients with HAA receiving blood
transfusions increases with the duration and number of
transfusions, and is therefore probably transfusion related
[21]. Taking these data into account and considering our
patient’s clinical course (normal liver function tests at
presentation, late onset of AA), it is unlikely that the
HCV infection alone was the cause of his ensuing AA.
Bone marrow aplasia may also occur as an idiosyn-
cratic drug reaction, with a sudden onset after several
months of therapy, and it is usually irreversible. In this
regard, two cases of patients with bone marrow hypopla-
sia and fibrosis following IFN-a treatment have been
reported in the literature [22]. A severe and persistent
pancytopenia has also been described in a 42-year-old
woman with a non-Hodgkin’sl y m p h o m af o l l o w i n ga
course of 10 days of intramuscular leukocyte IFN-a [23].
Figure 1 A bone marrow biopsy showing the absence of
hematopoietic tissue and its replacement with fat. Hematoxylin
& eosin staining. 20× magnification.
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a patient with multiple sclerosis [24]. However, to date,
there have been no reports of patients with severe AA
associated with PEG-IFN-a 2a in chronic HCV infection.
Some reports have suggested a genetic predisposition
to bone marrow injury in patients with an idiosyncratic
drug reaction. In such cases, direct toxicity may occur,
possibly due to genetically determined differences in
metabolic detoxification pathways [25,26]. Interestingly,
t h em o s tc o m m o n l yu s e dd o s eo fI F N - a in humans
inhibits cytochrome P450, thus decreasing the hepatic
clearance of some drugs, and this inhibition persists
during IFN-a therapy leading to various forms of hepa-
tic and extrahepatic toxicity [27].
On the other hand, clinical characteristics and circum-
stantial evidence suggest that idiosyncratic drug reac-
tions are caused by reactive metabolites and are
immune-mediated. The possible mechanisms of stem
cell damage by drug-mediated immune damage have
not been clearly defined. One suggestion mechanism is
the ‘spoiled membrane hypothesis’,w h i c he n v i s a g e s
aberrant stem cell antigens as a result of drug action
[28]. Another possibility that has not been widely
explored is that drug-induced AA is uncommon because
it requires a coincident event at or near the time the
drug is given. We could speculate that such an event
might be a virus infection such as with HCV. Therefore,
we suggest that the combination of a specific environ-
mental precipitant represented by the HCV infection, an
aberrant expression of cellular proteins in the patient’s
b o n em a r r o wc e l l sc a u s e db yad i s t u r b e dP E G - I F N - a
2a-associated drug metabolic detoxification pathway,
and a facilitating genetic background (specific HLA
genes) offering a more effective presentation of viral and
drug metabolites to the T cells conspired, possibly
synergistically, in the initiation of the destructive
immune attack towards the patient’s bone marrow cells
and the development of severe AA in our patient.
The approach to treating a patient with medication-
induced AA entails stopping the offending drug while
supporting the patient during the period of pancytope-
nia. The therapeutic issue revolves around the dilemma
of a period of initial observation versus aggressive ther-
apy, such as immunosuppression or bone marrow trans-
plantation. Waiting for a week and then conducting a
repeat bone marrow biopsy may avoid potential side
effects associated with the therapy without foreclosing
on a definitive treatment, which is to be promptly insti-
tuted in the absence of signs of recovery.
Conclusions
We present a case of a 46-year-old man who developed
severe AA while being treated with PEG-IFN-a 2a for
chronic HCV infection. To the best of our knowledge, this
is the first report of a patient with this complication asso-
ciated with PEG-IFN-a 2a in the growing body of litera-
ture. As health care providers, physicians should be aware
of this rare but life-threatening complication of PEG-IFN-
a 2a treatment.
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